Pfizer Inc. has described acetyltransferase KAT2A and/or KAT2B inhibitors reported to be useful for the treatment of cancer.

Cascade Pharmaceuticals Inc. has divulged free fatty acid receptor 1 (FFAR1; GPR40) agonists reported to be useful for the treatment of diabetes.

Kestrel Therapeutics Inc. has identified GTPase KRAS inhibitors reported to be useful for the treatment of cancer.

Euregen Biopharma Co. Ltd. has synthesized S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors reported to be useful for the treatment of cancer.

Researchers at Semmelweis University and University of Szeged have disclosed aminoalkylated benzoxy compounds acting as potassium channel blockers reported to be useful for the treatment of atrial fibrillation and ventricular arrhythmia.

Mayo Foundation for Medical Education and Research (MFMER) has described glycogen synthase kinase 3 (GSK-3) inhibitors reported to be useful for the treatment of cancer, neurological and psychiatric disorders.

Scientists at GT Apeiron Therapeutics and Shanghai Apeiron Biotechnology Co. Ltd. have divulged protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.

Fujimoto Pharmaceutical Corp. has identified dioxopiperidine derivatives reported to be useful for the treatment of cancer.

Shenzhen Bay Laboratory has synthesized G protein-coupled receptor GPR139 agonists reported to be useful for the treatment of Parkinson’s disease, epilepsy, pain, depression, schizophrenia, substance abuse and dependence, post-traumatic stress and autism spectrum disorders.

Valo Health Inc. has disclosed sphingosine 1-phosphate receptor 1 (S1P1 receptor; EDG1) agonists reported to be useful for the treatment of multiple sclerosis, psoriasis, amyotrophic lateral sclerosis, systemic lupus erythematosus, ulcerative colitis, lymphopenia and Crohn’s disease.